medigraphic.com
ISSN 1405-8790 (Impreso)

2010, Número 2

<< Anterior Siguiente >>

Rev Mex Med Fis Rehab 2010; 22 (2)


Neurorrehabilitación del paciente con esclerosis múltiple

Juárez SG

Idioma: Español
Referencias bibliográficas: 53
Paginas: 41-53
Archivo PDF: 419.17 Kb.


RESUMEN

Revisar los conceptos actuales de la esclerosis múltiple en sus diversas formas de presentación, evolución, y pronóstico así como describir alternativas de tratamiento médico y de rehabilitación, conjuntando una guía terapéutica-fisiátrica, en nuestra población mexicana, tanto en los pacientes hospitalizados como los manejados en la consulta externa, ya que como es bien sabido la neurorrehabilitación es parte sustancial del tratamiento médico integral a fin de mejorar y eficientar la calidad de vida de los pacientes con este padecimiento neurológico-degenerativo del sistema nervioso, altamente discapacitante.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hohlfeld R. Immunotherapy of multiple sclerosis. Brain 1997; 120: 865-916.

  2. Bender del BJE, Hernández GE, Barnes DJA, León PM, Concepción GB. Bioética, restauración neurológica y esclerosis múltiple. Revista Mexicana de Neurociencia 2002; 3(1): 27.

  3. Barrios MD. Resignificar lo masculino. Vila Editores, Primera edición, México, 2003.

  4. Enciclopedia Médico-quirúrgica 26-472-A-10 Kinesiterapia, Medicina Física.

  5. Velásquez QM, Macias IMA, Rivera OV, Lozano ZJ. Esclerosis múltiple en México: un estudio multicéntrico. Revista de Neurología 2003; 36(11): 1020.

  6. Poser CM, Paty DW, Scheinberg Let al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227.

  7. MacKay RP, Hirano S. Forms of benign multiple sclerosis: Report of two “clinically silent” cases discovered at autopsy. Arch Neurol 1967; 17: 588.

  8. Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983; 40: 533.

  9. Gómez L, Macías R, Mustelier R, Estrada R, Gámez L, Paz L. Disfunción corticospinal en la esclerosis múltiple y en las enfermedades de la neuromotora investigada mediante potenciales evocados motores. Rev Neurol 1996; 24(136): 1507-1512.

  10. Mayr N, Baumgartner C, Zeithofer J, Deecke L. The sensitivity of transcranial magnetic stimulation in detecting pyramidal tract lesions in clinically definite multiple sclerosis. Neurology 1991; 41: 566-569.

  11. Adachi K, Kimamoto T, Araki S. Elevated soluble Interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol 1990; 28: 687-691.

  12. Gallo P, Piccino M, Pagni S, Tavolato B. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients.

  13. Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of MS. N Engl J Med 1993; 329: 164-9.

  14. Sellebjerg F, Frederiksen JL, Nielsen PM et al. Double blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-534.

  15. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 655-661.

  16. Hughes RAC. Treatment of multiple sclerosis with azathioprine. In: Rudick RA, Goodkin DE eds. Treatment of multiple sclerosis. London. Springer-Verlag 1992: 157-17.

  17. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.

  18. Fuller KJ, Dawson K, Wiles CM. Physiotherapy in chronic multiple sclerosis. A controlled trial. Clin Rehabil 1996; 10: 195-204.

  19. Herndon RM, Rudick RA. Multiple sclerosis: The spectrum of severity. Arch Neurol 1986; 50: 531.

  20. Granger CV, Cotter AC, Hamilton BB, Fiedler RC, Hens MM. Functional assessment scales: a study of persons with multiple sclerosis. Arch Phys Med Rehabil 1990; 71: 870-5.

  21. Haber A, la Rocca N. Minimal record of disability of sclerosis multiple. New York: National MS Society, 1985.

  22. Kurtzke JF. Rating neurologic impairment in MS: an expanded disability expanded status scale (EDSS). Neurology 1983; 33: 1444-1452.

  23. Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. Journal of Consulting and Clinical Psychology 1985; 53: 103-110.

  24. Granger CV. Health accounting-functional assessment of the long-term patient. In: Kottke FJ, Stillwell GK, Lehman JF (eds). Krusen Handbook of Physical Medicine and Rehabilitation. 3rd Philadelphia, WB Saunders, 1982: 253-274.

  25. Archivo y expediente clínico Unidad de Medicina Física y Rehabilitación Centro “Hospital Colonia” Instituto Mexicano del Seguro Social.

  26. Cobble ND, Grigsby J, Kennedy PM. Rehabilitation of the patient with multiple sclerosis. In: DeLisa JB, ed. Rehabilitation medicine: principles and practice. Philadelphia: Lippincott; 1993: 861-85.

  27. Beuret-Blanquart NF, Weber J, Grise P. Les autosondages proles intermittens Dans les neurovesies. Conc Med 1985; 107: 3207-3210.

  28. Fakacs C, Audic B, Bournaud M, Dèsert JF, Esnault G, le Mouel MA, Mazières L, Perrigot M, Rhein F Weber J et al. –Rèèducation des neurovessies. –Encycl. Mèd. Chir. (Elsevier, Paris-France), Kinèsithèrapie physiqye. Rèadaptation 1992; 26-496-A-10: 26.

  29. Procedimientos de manejo de intestino neurogénico, Unidad de Medicina Física y Rehabilitación Centro Instituto Mexicano del Seguro Social.

  30. Multiple Sclerosis. Consensus Conference organized by the French Federation for Neurology. Rev Neurol (Paris) 2001; 157: 713-21.

  31. Terré-Boliart R, Orient-Lopez F. Rehabilitación en la EM. Rev Neurol 2007; 44(7): 426-431.

  32. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, FrancisGS, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997; 54: 731-6.

  33. Jankovic J, Brin MF. Therapeutic uses of botulim toxin. N Engl J Med 1991; 324: 1186-94.

  34. Watanabe Y, Bakheit AM, McLlellan DL. A study of the effectiveness of botulinum toxin type A in management of spasticity. Disabil Rehabil 1998; 20: 62-65.

  35. Andrés DJ. Dolor musculoesquelético: Tratamiento intramuscular con toxina botulínica. Dolor 2000; 15(1): 25-28.

  36. López de Val LJ, Castro GA. Toxina Botulínica. Aplicaciones terapéuticas. Editorial Masson Barcelona España.

  37. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-61.

  38. Volzt MI, Sauer H. Gabapentin leads to remission, of somatoform pain disorders with major depression pharmaco. Pyschiatry 1999; 32: 255-7.

  39. Wolf BG. Occupational theraphy for patients with multiple sclerosis. In Maloney FP, Burks JS, Ringel SP (eds): Interdisciplinary rehabilitation of multiple sclerosis and neuromuscular disorders. Philadelphia JB Lippincott, 1985: 103-218.

  40. Kidd D, Howard SR, Lossef, Thompson AJ. The benefit of inpatient neurorehabilitation in multiple sclerosis. Clin Rehabil 1995; 74: 612-620.

  41. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction. Neurology 1991; 41: 685-691.

  42. Barrero SCL, García AS, Ojeda MA. Índice De Barthel (IB), un instrumento esencial para la evaluación y la rehabilitación. Plast Rest Neurol 2005; 4(1-2): 81-85.

  43. Ruttenberg N. Assessment and treatment of speech and swallowing problems in patients wit sclerosis multiple. In: Maloney FP, Burk JS, Ringel SP. (eds) Philadelphia, JB, Lippincott, 1985.

  44. Paty D, Hartung H, Ebers G et al Management of relapsing-remiting multiple sclerosis diagnosis and treatment guidelines. Eur J Neu 1999; Supl. S1-S35.

  45. Kraft GH. Movement disorders. In: Basmajian JV, Kirby L (eds). Medical Rehabilitation, Baltimore, Williams & Wilkins, 1984: 19-33.

  46. Liversedge LA. Treatment and management of multiple sclerosis. Br Med Bull 1977; 33: 78-83.

  47. Wolf BG. Occupational therapy for patients with multiple sclerosis. In Maloney FP, Burks JS, Ringel SP (eds): Interdisciplinary rehabilitation of multiple sclerosis and neuromuscular disorders. Philadelphia JB Lippincott, 1985: 103-218.

  48. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997; 54: 731-6.

  49. Solari A. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 2000; 54(6): 1396.

  50. Lord SE, Wade DT, Halligan PW. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin Rehabil 1998; 12(6): 477-86.

  51. Patti F, Ciancio MR, Cacopardo M, Reggio E, Fiorilla T, Palermo F et al. Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients, randomized controlled trial. J Neurol 2003; 250: 861-6.

  52. Naranjo C. La vieja y novísima gestalt, cuatro vientos, Santiago de Chile, 1990.

  53. Barrios MD. Amor pareja y erotismo, sociedad humana de sexología humanista integral AC, México 1994-2002.




2020     |     www.medigraphic.com